What question did this study set out to answer?

To assess the safety, tolerability, and anti-tumor activity of CTX-8371 in patients with advanced malignancies post immune checkpoint inhibitors.

Phase 1 dose escalation of CTX-8371, a novel PD-1×PD-L1 bispecific antibody, in patients with advanced malignancies post checkpoint inhibition.

View Full Paper

Ask AI

Bookmark

To assess the safety, tolerability, and anti-tumor activity of CTX-8371 in patients with advanced malignancies post immune checkpoint inhibitors.
First-in-human study (NCT06150664) with a 3+3 dose-escalation design.
Administered CTX-8371 intravenously every two weeks at doses ranging from 0.1 to 10.0 mg/kg.
Included patients with metastatic melanoma, NSCLC, HNSCC, HL, and TNBC who failed previous treatments.
Out of 15 enrolled patients, the ORR was 20% and DCR was 60% after treatment with CTX-8371.
Median treatment duration was 9.8 months, with no dose-limiting toxicities observed.
Maximum tolerated dose was not reached; adverse events were primarily Grade 1/2.

No takes yet. Share an insight, caveat, or question.

Randomized trial evaluates safety and efficacy of CTX-8371 in advanced malignancies, suggesting potential for further development.

Wang et al. (2026) studied this question.

View Full Paper

Ask AI

Bookmark